A novel predictor of short-term prognosis in acute pulmonary embolism: inflammatory burden index
Therapeutic Advances in Cardiovascular Disease · 2026
DOI: 10.1177/17539447251407467 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Therapeutic Advances in Cardiovascular Disease, 2026. Verfasst von Lingwei Huang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Geriatrics, The Affiliated Yongchuan Hospital of Chongqing Medical University, Yongchuan, Chongqing, China. Hauptthemen laut MEDLINE: Pulmonary Embolism, Inflammation Mediators, Inflammation. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: chongqing municipal health commission, Yongchuan District Science and Technology Bureau.
Abstract (Originalsprache)
Background
Inflammation significantly impacts disease progression and prognosis in acute pulmonary embolism (APE); however, the optimal method to quantify this inflammation for prognostic purposes remains unclear.
Objectives
We aimed to identify the most effective blood-based inflammatory marker for predicting short-term mortality in patients with APE.
Methods
We retrospectively analyzed 301 patients with APE. We compared the predictive performance of nine inflammatory markers for 30-day mortality, focusing on the inflammatory burden index (IBI), and contrasted it with the standard clinical score (sPESI).
Results
After adjusting for potential confounders, a higher IBI was strongly and independently associated with an increased risk of 30-day mortality. IBI demonstrated superior predictive ability compared with all other inflammatory markers and the sPESI score. The relationship between IBI and mortality risk was linear; higher IBI values corresponded to greater mortality risk.
Conclusion
IBI is a robust and independent predictor of short-term survival in patients with APE. Calculated from routine blood tests (C-reactive protein, neutrophil, and lymphocyte counts), it offers a simple, rapid, and cost-effective tool that may enhance early risk stratification and guide personalized treatment decisions in clinical practice. Further validation in independent cohorts is required to confirm its prognostic utility.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Geriatrics, The Affiliated Yongchuan Hospital of Chongqing Medical University, Yongchuan, Chongqing, China.
- Chongqing Municipality Clinical Research Center for Geriatric Diseases (Yongchuan Hospital, Chongqing Medical University), Yongchuan, Chongqing, China.
- Department of Internal Medicine, Sichuan University Hospital, Sichuan University, Chengdu, Sichuan, China.
- Department of Clinical Pharmacy, West China Hospital of Sichuan University, Chengdu, Sichuan, China.
- Department of General Practice, The Affiliated Yongchuan Hospital of Chongqing Medical University, Yongchuan, Chongqing, China.
- Department of Geriatrics, The Affiliated Yongchuan Hospital of Chongqing Medical University, Yongchuan, Chongqing 402160, China.
ORCID-Profile: Lingwei Huang, Fei He
Förderung
- chongqing municipal health commission
- Yongchuan District Science and Technology Bureau
Zitieren
APA
Huang, L., Xiao, D., Yang, M., Wu, Z., & He, F. (2026). A novel predictor of short-term prognosis in acute pulmonary embolism: inflammatory burden index. Therapeutic Advances in Cardiovascular Disease. https://doi.org/10.1177/17539447251407467
Vancouver
Huang L, Xiao D, Yang M, Wu Z, He F. A novel predictor of short-term prognosis in acute pulmonary embolism: inflammatory burden index. Therapeutic Advances in Cardiovascular Disease. 2026. doi:10.1177/17539447251407467
BibTeX
@article{Huang2026,
author = {Huang, Lingwei and Xiao, Dan and Yang, Meimei and Wu, Zixing and He, Fei},
title = {A novel predictor of short-term prognosis in acute pulmonary embolism: inflammatory burden index},
journal = {Therapeutic Advances in Cardiovascular Disease},
year = {2026},
doi = {10.1177/17539447251407467}
}
EUVIMED